HC Wainwright Has Positive Estimate for Surrozen Q3 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Research analysts at HC Wainwright raised their Q3 2025 EPS estimates for shares of Surrozen in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.17) per share for the quarter, up from their previous estimate of ($1.21). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($2.83) EPS, FY2026 earnings at ($4.84) EPS, FY2027 earnings at ($5.59) EPS, FY2028 earnings at ($6.46) EPS and FY2029 earnings at ($7.29) EPS.

Surrozen Trading Up 7.9%

Shares of NASDAQ:SRZN opened at $10.85 on Thursday. The company has a market capitalization of $92.88 million, a price-to-earnings ratio of -0.75 and a beta of 0.60. Surrozen has a 12 month low of $5.90 and a 12 month high of $18.17. The firm’s 50-day moving average is $9.20 and its 200 day moving average is $9.84.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.09. The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 274.42% and a negative return on equity of 545.43%.

Hedge Funds Weigh In On Surrozen

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares during the period. Heights Capital Management Inc. purchased a new stake in Surrozen in the 1st quarter valued at about $524,000. Armistice Capital LLC purchased a new stake in Surrozen in the 2nd quarter valued at about $536,000. Trustees of Columbia University in the City of New York purchased a new stake in Surrozen in the 4th quarter valued at about $688,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Surrozen in the 4th quarter valued at about $928,000. 66.57% of the stock is currently owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.